Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Benmelstobart + AG in metastatic pancreatic cancer
NCT06621095Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, benmelstobart, sponsored by Renji Hospital. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
Beyond the preview
Go deeper on NCT06621095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621095.